|
| |
Human Genome SciencesThe mission of Human Genome Sciences is to discover, develop, manufacture and market innovative drugs that serve patients with unmet medical needs, with a primary focus on protein and antibody drugs. Clinical Development Pipeline
The HGS clinical development pipeline includes drugs to treat hepatitis C, lupus, anthrax disease, cancer, rheumatoid arthritis and HIV/AIDS. The Company’s primary focus is rapid progress toward the commercialization of our two lead products, Albuferon for hepatitis C, and LymphoStat-B for lupus. We have entered into collaboration agreements with two of the world’s leading pharmaceutical companies for the co-development and co-commercialization of these products. Our Albuferon collaborator is Novartis. Our LymphoStat-B collaborator is GlaxoSmithKline. We expect both Albuferon and LymphoStat-B to advance to Phase 3 clinical trials in 2006.
| Contact Details: |
| 14200 Shady Grove Road |
| Rockville |
| Maryland |
| 20850 |
| United States of America |
| Tel: | (301) 309-8504 |
| Fax: | (301) 309-8512 |
| Email: | |
| WWW: | www.hgsi.com/
|
|
Loading...
|
Recent Publications by Human Genome Sciences: |  |
Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) receptor-1 and receptor-2 agonists for cancer therapy.
Importance of the field: Agents that activate the TNF-related... | 28th October, 2009
| Human Genome Sciences, 14200 Shady Grove Road, Rockville, MD, 20850, USA
| Expert Opin Biol Ther. 2009 Oct 27.
DOI Direct Link |
Raxibacumab for the treatment of inhalational anthrax.
BACKGROUND: Inhalational anthrax caused by Bacillus anthracis is... | 21st July, 2009
| Human Genome Sciences,
| N Engl J Med. 2009 Jul 9;361(2):135-44.
DOI Direct Link |
Mapatumumab and lexatumumab induce apoptosis in TRAIL-R1 and TRAIL-R2 antibody-resistant NSCLC cell lines when treated in combination with bortezomib.
Mapatumumab and lexatumumab are fully human monoclonal antibodies that... | 25th March, 2009
| Oncology Research Department, Human Genome Sciences, Inc., Rockville, MD
| Mol Cancer Ther. 2009 Feb;8(2):292-302. Epub 2009 Jan 27.
DOI Direct Link |
High cell density and productivity culture of Chinese hamster ovary cells in a fluidized bed bioreactor.
A recombinant Chinese hamster ovary clone was cultivated in a 2L Cytopilot... | 13th November, 2008
| Human Genome Sciences, Inc., 9410 Key West Ave., Rockville, MD, 20850,
| Cytotechnology. 1999 May;29(3):215-20.
DOI Direct Link |
Potent in vitro activity of the albumin fusion type 1 interferons (albumin-interferon-alpha and albumin-interferon-beta) against RNA viral agents of bioterrorism and the severe acute respiratory syndrome (SARS) virus.
BACKGROUND: The type 1 interferons (INF-alpha and INF-beta) are potent... | 13th August, 2008
| Human Genome Sciences, Inc., Rockville, MD 20850, USA.
| Chemotherapy. 2008;54(3):176-80. Epub 2008 Jun 18.
DOI Direct Link |
→View more Human Genome Sciences research publications. |
Press Releases on Human Genome Sciences:
|
 |
| The Lupus Foundation of America Hosts Special Webinar to Discuss BENLYSTA(TM) Results |
25th November, 2009 |
Lupus Foundation of America |
WHAT: The Lupus Foundation of America (LFA) invites those living with lupus to a special Webinar with LFA's Medical Director, Dr. Joan Merrill. Human Genome Sciences (HGSI) and GlaxoSmithKline
|
| Reportlinker Adds Regenerative Medicine - Global Market Trends |
25th November, 2009 |
Reportlinker |
NEW YORK, Nov. 25 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:
Regenerative Medicine - Global Market Trends
http://www.reportlinker.com
|
| Wound Management Technologies (OTCBB: WNDM) Reports Revenue Increase of 33.5%; Posts Evidence-Based Studies for CellerateRx; and Business Update |
23rd November, 2009 |
Wound Management Technologies, Inc. |
FORT WORTH, Texas, Nov. 23 /PRNewswire-FirstCall/ -- Wound Management Technologies, Inc., (OTC Bulletin Board: WNDM) a rapidly growing provider of specialty medical products, announced that it has
|
| Aegera Therapeutics Initiates a Randomized Phase 2B Study with AEG35156 for the Treatment of Acute Myeloid Leukemia (AML) |
19th November, 2009 |
AEGERA THERAPEUTICS INC. |
MONTREAL, Nov. 19 /PRNewswire/ - Aegera Therapeutics Inc. announced today the dosing of the first patient in a randomized Phase 2B study of AEG35156, a targeted antisense therapeutic in mid-stage
|
| OTCBB-WNDM Announces Activation of BioPharma Division to Solicit Technology and Development Partners |
11th November, 2009 |
Wound Management Technologies, Inc. |
FORT WORTH, Texas, Nov. 11 /PRNewswire-FirstCall/ -- Wound Management Technologies, Inc., (WNDM), announced today that its BioPharma Management Technologies Division will search for partners to aid in
|
BioPortfolio Ltd provides targeted e-mail address lists for the life science sector - we can enable you to contact around 31 individuals from Human Genome Sciences using this service.  Contact BioPortfolio for a quote for a customised Excel verision of BioCorporate or BioEmail databases.
This page has been viewed 450 times since April 2007, the link to the organisation's website has been followed 48 times Recent Search Terms used to find this page: anthrax vaccine human genome sciences | HGS HDGNR10 clinical trial | CCR5 HGS clinical trials HDGNR10 | hgsi 2009 | . Search for more companies in Rockville Search for more companies in Maryland This site uses Thumbshots previews, resources from the NCBI applied. Maps are centred on zip/postcodes and should not be relied upon for exact building locations. Some information on this page has been collected automatically and may not have been verified.BioPortfolio search results for Human Genome Sciences |
